论文部分内容阅读
肿瘤过继性细胞免疫治疗是近年来不断发展的一种新的肿瘤治疗法。秉承继往IL-2活化杀伤性淋巴细胞(LAK)方法、肿瘤浸润淋巴细胞(TIL)方法,现今在明晰了细胞因子作用机制以后又创建了树突细胞共培养细胞因子诱导杀伤细胞(dendritic cell and cytokine induced killer,DC-CIK)治疗肿瘤的方法。其方法主要为取淋巴细胞同IL-4、GM-CSF、抗CD3抗体、IL-2、IL-1、IFN-γ、TNF-α等细胞因子共培养,通过刺激免疫效应细胞有效增殖以后分次回输给患者,达到增强免疫力、增强杀伤肿瘤细胞的效果。本文主要从LAK、TIL和DC-CIK三种方法的发展、效应淋巴细胞的作用、诱导和回输途径以及治疗效果的评价等方面进行综述。
Tumor cell adoptive immunotherapy is a continuous development in recent years, a new cancer treatment. Adhering to the following IL-2-activated lymphocyte (LAK) method and tumor infiltrating lymphocyte (TIL) method, dendritic cells are now cocultured with dendritic cells and cytokine induced killer (DC-CIK) for the treatment of tumors. The method is to take lymphocytes co-cultured with cytokines such as IL-4, GM-CSF, anti-CD3 antibody, IL-2, IL-1, IFN-γ and TNF-α and then stimulate the effective proliferation of immune effector cells Times back to the patient, to enhance immunity, enhance the effect of killing tumor cells. This article mainly reviewed the development of three methods of LAK, TIL and DC-CIK, the effects of effector lymphocytes, the pathways of induction and reinfusion and the evaluation of therapeutic effects.